Taken together, our results demonstrate that the ErbB2-specific antibody toxin scFv(FRP5)-ETA can be safely administered intravenously at doses up to 12.5 μg/kg per day to treat cancer patients with ErbB2-overexpressing tumors. The gene discussed is ERBB2; the disease is cancer.